Andrew Huberman

Evidencia en humanos

“And there are a lot of studies in rats, in mice, and a few other species as well. To my knowledge, there is only one study on humans and it's not a clinical trial. And frankly, it's not the best performed study and that's putting it mildly.”

Contexto: Lo dice al describir que la literatura sobre BPC-157 empieza hacia 1993 y se basa abrumadoramente en animales. Añade que «we actually have essentially no human data» (prácticamente no tenemos datos en humanos) pese a su uso generalizado.

Precaución con el cáncer

“In other words, BPC-157 is a potential tumor growth risk. So if you have knowledge of a given cancer or you're concerned about tumors at all, I would encourage you to be very cautious about the use of BPC-157.”

Contexto: Parte de su explicación de que los efectos proangiogénicos (VEGF) y sobre el receptor de la hormona del crecimiento descritos en animales podrían, en teoría, favorecer también tumores ya existentes.

Quién debe tener cuidado (todos los secretagogos de GH)

“If you're younger than 30, I don't know why you'd want to augment growth hormone unless you and your doctor decide that there's a clinical need or some other urgent need to do so because you're already making a lot of growth hormone. If you're older than 30 and you're interested in using these compounds, to me it stands to reason that of course you want to make sure that you don't have any tumors or cancers that you could potentially exacerbate. But in addition to that, that you really think about using the minimal effective dose and that you use perhaps even the mildest of these different compounds […]”

Contexto: Dicho en su resumen final sobre los secretagogos de la hormona del crecimiento como grupo (sermorelin, tesamorelin, CJC-1295, ipamorelin y otros), no solo sobre este compuesto.

También aparece en: Tesamorelin, CJC-1295, Ipamorelin

Uso aprobado

“This goes by the brand name Egrifta and it's an FDA approved drug for the reduction of visceral adiposity in HIV patients.”

Contexto: Su introducción a tesamorelin.

Muerte en un ensayo clínico

“But, keep in mind that CJC-1295 has entered clinical trials. There was a death within one of the clinical trials that was related to cardiovascular dysfunction. It's known to cause some fluid retention and increased fluid volume, which may have been related to that cardiovascular death. We don't know, okay? This is all kind of speculation.”

Contexto: La redacción sigue la transcripción oficial de hubermanlab.com; los subtítulos de YouTube dicen «which may be have been related».

Por qué no lo elegiría

“And to my mind, given that there are decent alternatives in sermorelin or tesamorelin, I don't know why anyone would specifically select CJC-1295 until all these safety issues have been resolved.”

Contexto: Comentario final de su bloque sobre CJC-1295.

Combinar ipamorelin con CJC-1295

“While I'm not opposed to that approach, you just want to make sure that the dosing, or I should say the relative dosing of each peptide is such that, you know, you're avoiding unnecessary increases in prolactin and cortisol, and that you're not hitting a pathway redundantly.”

Contexto: Dicho sobre quienes combinan ipamorelin con CJC-1295.

También aparece en: Ipamorelin

Hambre

“Ipamorelin is in this category two. So, it's definitely going to increase ghrelin, which is going to increase hunger.”

Contexto: «Category two» es su etiqueta para los secretagogos que imitan a la grelina.

Sueño

“It also tends to really improve sleep, but again, by increasing the amount of deep sleep. We don't know whether or not it does that […] at the expense of rapid eye movement sleep.”

Contexto: La omisión elimina un lapsus de los subtítulos («does that to at the expense»).

Evidencia en humanos

“But again, in the absence of clinical trials, we still don't know if and how they are working in humans. Nonetheless, a lot of people are now starting to take especially TB-500.”

Contexto: Dicho sobre BPC-157 y TB-500 juntos. No da ninguna dosis de TB-500 en todo el episodio.

¿Favorece el crecimiento?

“As far as I know, it isn't growth promoting. It doesn't impact the growth hormone pathway or other pathways associated with tissue growth.”

Contexto: Responde a afirmaciones en internet de que el TB-500 (que él equipara a la thymosin beta-4) favorece el crecimiento; en cambio, lo describe como implicado en la reparación de tejidos.

Aprobación y uso fuera de indicación

“And PT-141 is also known as the prescription drug Vyleesi. PT-141 or Vyleesi is FDA approved for the treatment of premenopausal hypoactive sexual desire. So this is FDA approved for the treatment of women that have suppressed libido. However men also will take Vyleesi for hypoactive sexual desire. This is obviously prescribed off-label […] but keep in mind as with the other peptides in this pathway, Vyleesi will stimulate pigmentation.”

Contexto: No da ninguna dosis. El corte elimina una muletilla.

Efectos secundarios de los péptidos melanocortínicos

“Now, there are some side effects associated with these compounds. Uh one of the more common ones is nausea, and that's because there are melanocyte stimulating um hormone receptors all throughout the gut. They can also cause flushing of the skin, and they can cause blood pressure to increase. Also, folks with melanoma should be very cautious about using any of the peptides that stimulate melanocytes because that could potentially exacerbate melanoma.”

Contexto: Dicho sobre el PT-141 y los péptidos melanotan en conjunto.

También aparece en: Melanotan II

Qué hace

“Melanotan 2 3 4 and 5 also lead to darkening of the skin by way of activating melanocytes in the skin but because they can cross the blood-brain barrier they cause effects that are at the level of psychology […]”

Contexto: Después describe efectos sobre el estado de ánimo, la libido y el apetito. No da ninguna dosis.

Su uso para la libido es una incógnita

“the use of kisspeptin to increase vitality and libido is a bit of a um let's just say it's a it's a little bit of a wild card. We don't yet know all the effects of kisspeptin.”

Contexto: Antes señala que la kisspeptin sintética se «prescribed for what’s called hypothalamic amenorrhea» (receta para la llamada amenorrea hipotalámica). No da ninguna dosis.

La evidencia procede sobre todo de animales

“There's some nice studies showing telomere expansion. There's some nice studies showing that several features of brain aging and body aging can indeed be partially offset by things like epithalamin peptides, but it is indeed a leap that people are taking when they are deciding or taking epithalamin in order to extend their life […] there are still no clinical trials that point directly to taking x amount of epithalamin several times per week as a way to extend life.”

Contexto: Justo antes dice que la idea «rests largely on the animal data» (se basa sobre todo en los datos en animales). El corte elimina una frase sobre cómo la evidencia está «cludged together» (hecha de retales).